MP50-02 HOW IMPORTANT ARE MORPHOLOGIC SUBTYPES ON THE PROGNOSIS OF SURGICALLY TREATED NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA? AN ANALYSIS FROM A CONTEMPORARY MULTI-INSTITUTIONAL DATABASE

Abstract

You have accessJournal of UrologyCME1 May 2022MP50-02 HOW IMPORTANT ARE MORPHOLOGIC SUBTYPES ON THE PROGNOSIS OF SURGICALLY TREATED NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA? AN ANALYSIS FROM A CONTEMPORARY MULTI-INSTITUTIONAL DATABASE Selcuk Erdem, Umberto Capitanio, Riccardo Campi, Daniele Amparore, Maria Carme Mir, Eduard Roussel, Nicola Pavan, Onder Kara, Tobias Klatte, Enes Degirmenci, Resat Aydin, Andrea Minervini, Sergio Serni, Alessandro Berni, Giacomo Rebez, and Faruk Ozcan Selcuk ErdemSelcuk Erdem More articles by this author , Umberto CapitanioUmberto Capitanio More articles by this author , Riccardo CampiRiccardo Campi More articles by this author , Daniele AmparoreDaniele Amparore More articles by this author , Maria Carme MirMaria Carme Mir More articles by this author , Eduard RousselEduard Roussel More articles by this author , Nicola PavanNicola Pavan More articles by this author , Onder KaraOnder Kara More articles by this author , Tobias KlatteTobias Klatte More articles by this author , Enes DegirmenciEnes Degirmenci More articles by this author , Resat AydinResat Aydin More articles by this author , Andrea MinerviniAndrea Minervini More articles by this author , Sergio SerniSergio Serni More articles by this author , Alessandro BerniAlessandro Berni More articles by this author , Giacomo RebezGiacomo Rebez More articles by this author , and Faruk OzcanFaruk Ozcan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002625.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Papillary renal cell carcinoma (papRCC) is currently divided in 2 morphologic subtypes: type 1 and type 2. The aim of this contemporary multi-institutional study is to investigate the role of morphologic subtypes on the prognosis of surgically treated non-metastatic papRCC. METHODS: This study was conducted using a multi-institutional database consisting of 1219 patients with histopathologically confirmed non-metastatic papRCC after partial or radical nephrectomy collected from 8 tertiary European insitutions. The patients with accurate data for morphologic subtypes (type 1 and type 2) and follow-up records were included into this study. Clinical and histopathological parameters, recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS) were compared between subtypes. Chi-square and Mann-Whitney U tests, and Kaplan-Meier survival analysis were used for the comparisons. Multivariable Cox Regression analysis was used to assess independent predictors on survival outcomes. RESULTS: A total of 879 patients were identified for this study. The patients in the type 2 group were older (64 vs. 66 years, p=0.006), had greater tumor size (3.8 vs. 4.3 cm, p=0.01) and more frequently underwent radical nephrectomy (25.7 vs. 35.2%, p=0.002). Nuclear grade (p<0.001), pathologic T stage (p<0.001) and N stage (p<0.001) were significantly higher in the type 2 group. The median follow-up was 48 (IQR:24-88) months. Kaplan-Meier survival analyses showed that 5 year RFS (90.3% vs. 76.7%, p<0.001), CSS (93.9% vs. 86.6%, p<0.001) and OS (88.1% vs. 81.0%, p=0.011) were significantly lower in type 2 papRCC. Age, grade, pathologic T and N stage adjusted Cox-Regression analyses found that type 2 was independent predictor for RFS (HR:1.78 [95%CI:1.22-2.58], p=0.003), but not for CSS (HR:1.54 [95%CI:0.93-2.56], p=0.094) and OS (HR:1.09 [95%CI:0.77-1.54], p=0.645). CONCLUSIONS: This contemporary multi-institutional study with a large dataset suggested that type 2 was associated with adverse histopathological outcomes, and was an independent predictor of RFS after surgical treatment of non-metastatic papRCC. These findings may guide decision making on follow-up schedule after surgery, and risk stratification for the adjuvant trials, in the individualized medicine era. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e863 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Selcuk Erdem More articles by this author Umberto Capitanio More articles by this author Riccardo Campi More articles by this author Daniele Amparore More articles by this author Maria Carme Mir More articles by this author Eduard Roussel More articles by this author Nicola Pavan More articles by this author Onder Kara More articles by this author Tobias Klatte More articles by this author Enes Degirmenci More articles by this author Resat Aydin More articles by this author Andrea Minervini More articles by this author Sergio Serni More articles by this author Alessandro Berni More articles by this author Giacomo Rebez More articles by this author Faruk Ozcan More articles by this author Expand All Advertisement PDF DownloadLoading ...